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We describe molecular convergence between BMI1
and CHD7 in the initiation of medulloblastoma.
Identified in a functional genomic screen in mouse
models, a BMI1High;CHD7Low expression signature
within medulloblastoma characterizes patients with
poor overall survival. We show that BMI1-mediated
repression of the ERK1/2 pathway leads to increased
proliferation and tumor burden in primary human MB
cells and in a xenograft model, respectively. We pro-
vide evidence that repression of the ERK inhibitor
DUSP4 by BMI1 is dependent on a more accessible
chromatin configuration in G4 MB cells with low
CHD7 expression. These findings extend current
knowledge of the role of BMI1 and CHD7 in medullo-
blastomapathogenesis, and they raise the possibility
that pharmacological targeting of BMI1 or ERK may
be particularly indicated in a subgroup of MB with
low expression levels of CHD7.INTRODUCTION
Medulloblastomas (MBs) are the most common malignant brain
tumors of childhood. Current standard of care consists of multi-
modal therapy (surgery with radio- and/or chemotherapy) that
does not take into account the specific molecular mechanisms
driving tumor growth. Despite a good overall survival rate,
long-term survivors face significant treatment-related morbidity
and reduced quality of life. Risk stratification of patients based2772 Cell Reports 21, 2772–2784, December 5, 2017 ª 2017 The Au
This is an open access article under the CC BY license (http://creativeon molecular subtyping and targeted therapies are essential to
reduce secondary effects and improve overall prognosis.
Gene expression profiling of large cohorts of MBs has
dissected this historically monomorphous tumor entity into four
distinct molecular subgroups (WNT, SHH, group 3, and group 4)
with divergent prognoses and responses to therapy (Taylor et al.,
2012). Recently, heterogeneity within these subgroups has been
reduced by two independent studies that have defined addi-
tional subtypes (Cavalli et al., 2017; Schwalbe et al., 2017). While
WNT, SHH, and group (G)3 MBs are well characterized molecu-
larly and have been shown to arise from topographically distinct
neural progenitor cells (reviewed in Leto et al., 2016), little is
known about the molecular and cellular mechanisms underpin-
ning the formation of G4 MB, although it is the most frequent
(Ramaswamy et al., 2016).
Oncogenic events affecting chromatin-modifying genes have
been described across the subgroups (Dubuc et al., 2013),
although different modifications are found in the specific sub-
groups and their frequency varies (Jones et al., 2013). Inactivat-
ing mutations in the histone demethylase KDM6A and loss-of-
function mutations in the Trithorax gene MLL3 (Northcott et al.,
2012) as well as elevated expression of the Polycomb proteins
EZH2 (Robinson et al., 2012) and BMI1 (Behesti et al., 2013)
were identified particularly in G4 MBs, raising the possibility
that increased Polycomb repression is an important step in the
pathogenesis of MBs and in particular of G4 tumors.
The Polycomb group protein BMI1 is a potent inducer of neural
stem cell self-renewal and neural progenitor cell proliferation
during development and in adult tissue homeostasis (Leung
et al., 2004). Numerous studies have demonstrated that BMI1,
which is upregulated in a variety of cancers, has a positive cor-
relation with clinical grade/stage and poor prognosis (Glinskythor(s).
commons.org/licenses/by/4.0/).
et al., 2005). BMI1 is overexpressed across all MB subgroups,
with the highest levels of expression detected in G4 tumors, fol-
lowed by G3, SHH, andWNT (Behesti et al., 2013). The growth of
G4 MBs is dependent on BMI1 expression, as BMI1 knockdown
results in reduced tumor growth and invasion in a xenograft
model (Merve et al., 2014). Also SHH MB growth is dependent
on BMI1 expression, as demonstrated by experimental genetic
approaches where crossing a mouse model of SHH MB onto
a Bmi1/ background neutralized tumor formation (Michael
et al., 2008). Intriguingly, we recently found that overexpression
of Bmi1 alone in cerebellar granule cell progenitors (GCPs), a cell
of origin of MB, is not sufficient to induce MB formation (Behesti
et al., 2013). As overexpression of Bmi1 driven by the pan-neural
Cre line Nestin-Cre did not yield MB formation (Yadirgi et al.,
2011), it is conceivable that additional oncogenic events are
required to collaborate with BMI1 to induce MB formation.
Here we used a Sleeping Beauty forward genetic approach in
the mouse to identify oncogenic events collaborating with Bmi1
overexpression to induce MB formation. We identify a molecular
convergence between Bmi1 and Chd7, an ATP-dependent chro-
matin remodeler that fine-tunes developmental gene expression
through modulating chromatin structure (reviewed in Basson
and van Ravenswaaij-Arts, 2015). Importantly, somatic muta-
tions in CHD7 have been described in G4 MBs (Robinson
et al., 2012), although their tumorigenicity in vivo has not been
proven. Here we show that CHD7 controls the proliferation of
G4 MB cells and its silencing renders them susceptible to
BMI1-mediated ERK1/2-induced proliferation control, raising
the possibility that BMI1 and/or ERK may be promising drug-
gable targets in this MB subgroup.
RESULTS
A Forward Genetic Screen IdentifiesChd7 as a Frequent
Insertion Site in MB Arising in Mice Overexpressing
Bmi1 in Cerebellar Progenitors
The Sleeping Beauty (SB) transposon-based mutagenesis sys-
tem, which uses a transposase and mutagenic transposon al-
leles to target mutagenesis to somatic cells of a given tissue in
mice, was used to identify random mutations capable of driving
tumor development. Mice overexpressing Bmi1 in glutamatergic
progenitors (Math1-Bmi1 transgenic line; Figures S1A and S1B)
were crossed to SB11;T2Onc2 (Copeland and Jenkins, 2010).
Triple-mutant mice as well as double-mutant controls were
generated and kept on tumor watch for 12 months. Ten of 53
Math1Bmi1;SB11;T2Onc2 mice developed MBs (18.9% inci-
dence), while only 3 MBs were detected in 47 SB11;T2Onc2
mice (6.4% incidence), in keeping with an increased tumorige-
nicity in the triple-mutant mice of 12.5% (Figure 1A). All tumors
had morphological and immunohistochemical characteristics
of MBs, as assessed by H&E stain and synaptophysin immuno-
staining (Figure 1B), and histological features were similar irre-
spective of their genotype.
Next, the tumors were analyzed for common transposon
insertion sites in genes (gCIS) to identify candidates that could
cooperate with Bmi1 in MB development (Data S1). A total of
41 recurrent clonal insertions were identified in MBs originating
in Math1Bmi1;SB11;T2Onc2, of which 7 were shared with apublished dataset of Sleeping Beauty-induced insertion sites
in MBs occurring in Ptch1+/ mice (Morrissy et al., 2016; Wu
et al., 2012) (Figure 1C). Among the 41 gCISs identified in
Math1Bmi1;SB11;T2Onc2, 27 were found to be significantly
(p < 0.05) enriched following Bmi1 overexpression and 3 of these
were shared between the two Sleeping Beauty-induced MB
models (Figure 1D). Sleeping Beauty insertions in Chromodomain
helicase DNA-binding factor 7 (Chd7) were inactivating insertions
andsowere themajority of insertions inPtprd, while themajority of
insertions in Zcchc7 were activating (Figure 1E). Chd7 is an ATP-
dependent chromatin remodeling factor (Bajpai et al., 2010);Ptprd
is a member of the protein tyrosine phosphatase (PTP) family
(Pulido et al., 1995); and Zcchc7 is a component of a nucleolar
TRAMP-like complex, an ATP-dependent exosome regulatory
complex (Lubas et al., 2011). Notably, inactivating insertions in
Chd7were significantly enriched in theMath1Bmi1;SB11;T2Onc2
MB model (3/6) as compared to the Ptch1+/;SB11;T2Onc2 MB
model (1/36) (p < 0.023) (Figure 1F). Immunostaining for Bmi1
and Chd7 in the Sleeping Beauty-induced MBs with Chd7 inser-
tions as compared to those without revealed similar and reduced
expression, respectively (Figures S1C and S1D).
Taken together, our data suggest that Bmi1 and Chd7 coop-
erate to induce MB in a mouse model.
A BMI1High;CHD7Low Molecular Signature Identifies a
Subgroup of G4 MBs with Reduced Overall Survival
Next, we screened primary humanmedulloblastoma samples for
CHD7 mutations. A collection of 830 primary human MBs pro-
filed on Affymetrix SNP6.0 copy number arrays and subgrouped
using Nanostring technology (Northcott et al., 2012) and 281 pri-
mary MBs subgrouped using next-generation sequencing (NGS)
across three independent cohorts (Jones et al., 2012; Pugh et al.,
2012; Robinson et al., 2012) were interrogated. Intriguingly, this
analysis identified a molecular convergence on single-copy loss
of CHD7 via hemizygous deletion (Figure 2A) or hemizygous
mutations (Figure 2B) in G4MBs, while no significant enrichment
for CHD7mutations was found in the SHH and WNT subgroups.
A graphical representation of the mutational inactivating events
that affect CHD7 is shown in Figure 2C.
Next, we examined the subgroup-specific expression levels of
BMI1 and CHD7 in a large transcriptomic dataset from primary
human MBs (n = 187, run on Affymetrix HT-HG-U133A arrays)
(Cho et al., 2011). While CHD7 was most highly expressed in
SHH MBs with relatively reduced expression in G3 and G4
MBs, the opposite patterns were observed for BMI1 (Figures
S2A and S2B). A Kaplan-Meier survival analysis demonstrated
that tumors with a BMI1High CHD7Low expression profile had a
significantly reduced overall survival as compared to MBs lack-
ing this profile (Figure 2D; p = 0.03028). When we examined this
relationship in amolecular subgroup-specificmanner, a reduced
overall survival was observed, particularly in G4 MBs with this
signature (Figure 2E; p = 0.00154). No significant contribution
to patients’ survival was observed when the relative contribution
of BMI1High or CHD7Low was considered (Figure S2C).
These data support the notion that the Bmi1/Chd7 molecular
convergence identified in mouse models reflects a potentially
pathogenically relevant mechanism underpinning a subgroup
of G4 MBs.Cell Reports 21, 2772–2784, December 5, 2017 2773
Figure 1. Identification of Oncogenic Events Cooperating with Bmi1 to Promote MB Development Using the Sleeping Beauty Transposon
System
(A) Kaplan-Meier survival analysis and summary of animal models used to assess the contributions of Bmi1 to MB development. The addition of Bmi1 over-
expression to SB11;T2Onc2 led to increased MB formation.
(B) Histology shows morphological (H&E) and immunohistochemical (Synaptophysin) features of MB in Math1-Bmi1;SB11;T2Onc2.
(C) Comparison of recurrent Sleeping Beauty insertions identified in Math1-Bmi1;SB11;T2Onc2 with those identified in Ptch1+/;SB11;T2Onc2 mice
(Morrissy et al., 2016) highlighted Chd7 as a recurrent clonal insertion.
(D) Bar graph representation of recurrent Sleeping Beauty insertions in Math1-Bmi1;SB11;T2Onc2 versus Ptch+/;SB11;T2Onc2 mice, highlighting events
significantly (p < 0.05) enriched following Bmi1 overexpression.
(E) Sleeping Beauty insertion maps for candidate genes identified in Math1-Bmi1;SB11;T2Onc2 mice, including Zcchc7 (activating and inactivating insertions),
Chd7 (inactivating insertions), and Ptprd (inactivating and activating insertions).
(F) Statistically significant enrichment of Chd7 insertions identified in the Math1-Bmi1;SB11;T2Onc2 MB model versus the Ptch1+/;SB11;T2Onc2 MB model.
Scale bar represents 2 mm (B, left) and 125 mm (B, center and right).
See also Figure S1.
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Figure 2. A BMI1High;CHD7Low Signature in
MB with Poor Prognosis
(A) Graphical representation of the percentage of
MB with CHD7 single-copy loss across subgroups
with enrichment in G4.
(B) CHD7 mutational analysis across molecular
subgroups.
(C) Graphical representation of the mutational in-
activating events that affect CHD7.
(D and E) Kaplan-Meier survival analysis demon-
strates that tumors with a BMI1High;CHD7Low
signature have a significantly (p = 0.03028)
reduced overall survival (D). When we examine this
relationship in a subgroup-specific manner, the
same trend (p = 0.00154) holds true for G4 MB (E).
See also Figure S2.CHD7 Controls Proliferation of G4 MB Cells In Vitro in a
BMI1-Dependent Fashion
Patient-derived MB lines, some of which have been maintained
as orthotopic xenografts (Zhao et al., 2012), were chosen to
further dissect this molecular signature. First, we confirmed the
subgroup affiliation by analyzing their gene espression against
a classifier (Robinson et al., 2012). Principal-component analysis
(PCA) of data obtained fromRNA sequencing (RNA-seq) analysis
confirmed that ICb1299, a line we have recently shown to be
dependent on BMI1 for growth and intraparenchymal invasion
in a xenograft model (Merve et al., 2014), and CHLA-01-Med
belong to G4 with a significant overlap with G3, while ICb1595
belongs to G3 (Figure 3A). These lines were chosen for further
analysis, and they were expanded and shortly maintained
in vitro to perform functional studies. Hierarchical clustering of
RNA-seq datasets of the cultured cells and the original datasets
obtained from the patient’s tumor (Zhao et al., 2012) confirmed
that, although some shift in gene expression did occur afterCell Repoin vitro culturing, they remained reason-
ably similar to the cells isolated from the
xenografts and retained their subgroup
affiliation (Figure S3A). Validation on inde-
pendent cultures confirmed very high
expression ofOTX2, a transcription factor
overexpressed in the majority of G4 MBs
(Bunt et al., 2010) in all three lines,
with concomitant high expression levels
of the G3/G4 markers (Lin et al., 2016)
LMX1A and LHX2 in CHLA-01-Med and
EOMEOS and LHX2 in ICb1595 (Fig-
ure 3B). The expression of MATH1,
GLI1, and GAB1, markers of granule
cell progenitors and SHH MBs (Ayrault
et al., 2010), was negligible in these
lines compared to two patient-derived
SHH MB lines, ICb984 and ICb1338
(Figure 3B).
Next, we compared the expression of
BMI1 andCHD7 in these lines with human
cerebellum, and we found similar expres-
sion levels for both genes in all MB linesand human cerebellum of early postnatal time points (newborn
and 2 months of age). In contrast, the expression of BMI1 was
higher in all lines compared to adult cerebellum, while it was
similar for CHD7 (Figure 3C). These findings verified that
ICb1299 and CHLA-01-Med are suitable models to test the
contribution of CHD7 to G4 MB pathogenesis in the context
of BMI1 overexpression. Line ICb1595 was also analyzed
further to dissect the specificity of the BMI1/CHD7 molecular
convergence to G4 MBs.
Lentivirus-mediated CHD7 knockdown (Figure S3B) resulted
in increased proliferation of all lines (Figure 3D), an effect that
was BMI1 dependent as it was neutralized by concomitant
BMI1 knockdown (Figure S3B; Figure 3D). Importantly, reconsti-
tution of CHD7 expression in ICb1299 after silencing (Fig-
ure S3D) brought proliferation back to basal level (Figures S3E
and S3F).
Together, these data indicate that CHD7 represses prolifera-
tion in G4 and G3 MB cells that overexpress BMI1.rts 21, 2772–2784, December 5, 2017 2775
Figure 3. Increased Proliferation upon CHD7 Silencing Is BMI1-Dependent in Non-WNT, Non-SHH MB Patient-Derived Cell Models
(A) Scatterplots of the first 3 principal components of the Robinson dataset (Robinson et al., 2012). Points are shaded based on their subgroup. Ellipses represent
the 99%confidence intervals of each subgroup, computed using the covariancematrix of each subset. RNA-seq data of G4 (ICb1299 andCHLA-01-Med) andG3
primary MB cells were subjected to the same PCA transformation and are shown in cyan, magenta, and black respectively.
(B) Heatmap representation of relative expression of selected MB markers in patient-derived cells (ICb1299 and CHLA-01-Med, G4; ICb1595, G3; and ICb1338
and ICb984, SHH). OTX2, EOMEOS, LMX1A, and LHX2 are mainly expressed by G4 and G3 cells, while GAB1, GLI1, andMATH1 are specifically expressed by
SHH cells.
(C) Expression of BMI1 and CHD7 in ICb1299, CHLA-01-Med, and ICb1595 patient-derived MB lines is comparable to their expression in the early postnatal
cerebellum (BMI1) and adult cerebellum (CHD7).
(D) Increased proliferation upon CHD7 silencing is BMI1 dependent (n = 3).
(E) Pathway analysis reveals different processes and pathways affected by silencing CHD7 and BMI1 individually or concomitantly.
(legend continued on next page)
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Genome-wide Expression Analysis Identifies CHD7 and
BMI1 as Key Regulators of Neuronal Differentiation and
Proliferation of G4 MB Primary Cells
To clarify the molecular mechanism mediating the synergistic
effect between CHD7 and BMI1 in MB differentiation and prolif-
eration, we carried out a genome-wide analysis of gene expres-
sion in the ICb1299 MB line. In particular, we set out to assess
the impact of silencing CHD7 in a BMI1-overexpressing G4
MB primary cell line (shCHD7) compared with the same primary
cell line treated with scrambled small hairpin RNA (shRNA) as a
control (Ctr versus shCHD7). The impact of silencing BMI1 in
shCHD7 cultures compared to silencing only CHD7 was also
assessed (shCHD7 versus shCHD7;shBMI1), in addition to an
evaluation of the impact of silencing BMI1 in the context of
CHD7 expression (Ctr versus shBMI1). 360 genes were differen-
tially expressed in Ctr versus shCHD7 (277 upregulated and
83 downregulated), 1,175 in shCHD7 versus shCHD7;shBMI1
(406 upregulated and 769 downregulated), and 584 in Ctr
versus shBMI1 (224 upregulated and 360 downregulated)
when thresholds of 0.05 for statistical significance and 0.6
for absolute log2 expression change were applied. First, we
confirmed that no changes in the subgroup-defining marker
expression were noted upon silencing CHD7 or BMI1 or both
(Figure S3C). Pathway analysis carried out on the MetaCore
platform highlighted different functions and pathways for these
three comparisons. Interestingly, different terms and path-
ways were impacted in the different conditions tested. In the
Ctr versus shCHD7 comparison, nervous system development,
synaptic transmission (gene ontology [GO] process), neuron
part, neuron projection (GO location), synaptic contact, trans-
mission of nerve impulse, neurogenesis, and chromatin conden-
sation in prometaphase (process networks) were significantly
enriched. Regulation of G1-S transition, regulation of angiogen-
esis (process networks), oxidative phosphorylation, and oxida-
tive stress (pathway maps) were highlighted for the comparison
shCHD7 versus shCHD7;shBMI1; and cell adhesion (pathways
maps) and cell cycle S phase and M phase as well as DNA
damage were impacted in the Ctr versus shBMI1 comparison
(Figure 3E).
Assessment of enrichment for Polycomb-group (PcG) targets
among the differentially expressed (DE) genes in CHD7-depleted
cells (using the statistical significant cutoff of p < 0.01) revealed
that 15 of the 68 DE genes were previously reported to possess
H3K27me3 on their promoters in mouse neural progenitor
cells (Mohn et al., 2008), representing a 2.62-fold enrichment
(p = 0.0035) (Figure 3F). Enrichments of 2.25-fold (p = 0.012)
and 4.8-fold (p value < 1e04) were found when the data were
compared with the proportion of PcG target genes in human
fibroblasts (Bracken et al., 2006) and in an MB dataset (Hoves-
tadt et al., 2014), respectively (Figure 3F). These results support
the notion that CHD7 functionally relates to the Polycomb com-
plex in MB.(F) Diagram representing the fold enrichment of PcG target genes in the cohort of g
in murine NPCs (Mohn et al., 2008), in human fibroblasts (Bracken et al., 2006),
represented as mean ± SEM.
See also Figure S3.Taken together, these data suggest that the differentiation
potential of MB G4 is controlled by CHD7 via direct or indirect
interplay with genes repressed by the Polycomb complex in
neural progenitors.
Comparative Analysis with G4 MB Datasets Reveals
Activation of ERK Pathway upon CHD7 Silencing via
BMI1-Mediated Repression of DUSP4
To identify the genes mediating the pro-proliferative effect of
CHD7 silencing in a BMI1-overexpressing context and to ensure
we were focusing on those relevant for MB patients, a compar-
ative analysis with the expression data of the G4 MB subgroup
of patients with a BMI1High;CHD7Low signature (Figure 2E) was
carried out. Five genes that were upregulated upon BMI1 knock-
down in the shCHD7 cell model were also expressed at a lower
level in the BMI1High;CHD7Low patient group compared to the
remaining patients, while 15 genes were downregulated in the
shCHD7;shBMI1 cell model and expressed at higher levels in
the BMI1High;CHD7Low patient group (Figure 4A; Figure S4A).
Pathway analysis carried out on the MetaCore platform for all
20 genes indicated ERK signal transduction as the most signifi-
cant pathway affected (Figure S4B). A literature review identified
DUSP4, HIF-1a, and COL8A2 as being linked to ERK signaling,
and analysis of a published dataset of chromatin immunoprecip-
itation sequencing (ChIP-seq) data for Bmi1 in neural stem cells
and glioblastoma cells identified Dusp4 as a direct Bmi1 target
gene (Gargiulo et al., 2013). Moreover, several members of the
DUSP gene family were upregulated in an RNA-seq dataset
comparing neural stem cells lacking Bmi1 versus control in the
mouse (Gargiulo et al., 2013). Upregulation of DUSP4 was
confirmed in both G4 MB lines upon silencing of BMI1 (Fig-
ure 4B), and a lower expression level of DUSP4 was confirmed
in the G4 MB subgroup with a BMI1High;CHD7Low signature (Fig-
ure 4C). Interestingly, no upregulation of DUSP4 expression was
noted in the G3MB line upon CHD7 silencing (Figure S4C). Next,
we assessed chromatin accessibility in the vicinity of the DUSP4
transcription start site (TSS) using the assay for transposase-
accessible chromatin (ATAC) method (Buenrostro et al., 2013).
Silencing of CHD7 increased DNA accessibility around the
DUSP4 TSS and the DUSP4 promoter (Figures 4D and 4E), a
configuration that was lost upon concomitant silencing of BMI1
(Figure 4E).
Western blot analysis for pERK1/2 and ERK1/2 demonstrated
pathway activation under conditions where BMI1 was expressed
and in a more pronounced fashion when CHD7 was silenced
(Figures 5A and 5B), in keeping with DUSP4 gene repression
by BMI1. Indeed, knockdown of BMI1 significantly reduced
ERK1/2 pathway activation in G4 MB lines (Figures 5A and 5B),
as predicted and in linewith the upregulation ofDUSP4 observed
in the genome-wide comparative expression analysis. Impor-
tantly, no overactivity of ERK signaling was found in the G3
MB line (Figure S5A), in keeping with no evidence of DUSP4enes deregulated in CHD7-depleted cells, as compared to the expected values
and in human MBs (Hovestadt et al., 2014), as previously reported. Data are
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Figure 4. Molecular Convergence on Activation of ERK-Signaling Pathway upon CHD7 Silencing Is Mediated by the Repression of DUSP4
by BMI1
(A) Comparative analysis with human MB datasets identified conserved DE genes in G4 MB cells upon BMI1 knockdown in a CHD7-silenced context and in G4
MB with a BMIHigh;CHD7Low signature. Venn diagram represents the analysis.
(B) Western blot analysis (top) and quantification (bottom) show CHD7 dependency of BMI1-mediated repression of DUSP4 in G4 MB cells. Histograms show
mean ± SEM (n = 3).
(C) Boxplot showing lower expression of DUSP4 in BMI1High;CHD7Low G4 MB.
(D) Assessment of DNA accessibility in the vicinity of the DUSP4 TSS by assay for transposase-accessible chromatin (ATAC). Schematic representation of the
promoter region of DUSP4 with primer locations is shown.
(E) Increased accessibility in CHD7-silenced cells is lost upon concomitant silencing of BMI1. Data are represented as mean ± SEM.
See also Figure S4.upregulation (Figure S4C). These data suggest a model
where CHD7 silencing increases chromatin accessibility at the
DUSP4 locus to facilitate BMI1-mediated repression and conse-2778 Cell Reports 21, 2772–2784, December 5, 2017quent ERK pathway activation in G4 MB. Under conditions
where both BMI1 and CHD7 are silenced, ERK pathway activa-
tion is down to baseline levels, a finding that is unlikely to be
Figure 5. The Pro-proliferative State of the G4 MB Cells upon Silencing of CHD7 Is Mediated by ERK1/2
(A) Overactivity of the ERK1/2-signaling pathway in ICb1299 CHD7-silenced cells is neutralized by concomitant BMI1 silencing.
(B) Similar effects are seen in CHLA-01-Med.
(legend continued on next page)
Cell Reports 21, 2772–2784, December 5, 2017 2779
mediated by DUSP4, as BMI1 and CHD7 are silenced and the
chromatin configuration at the locus is closed (Figure 4E).
To determine whether this BMI1-CHD7 connection also
applied to freshly isolated cells and is not a feature of cells main-
tained through several in vitro passages, we obtained neural
progenitor cells (NPCs) from human fetal brains. These cells ex-
pressed high levels of BMI1 as compared to adult cerebellum,
albeit not as high as G4 MB cells (Figure 5C; Figure S5C). We
found that the ERK1/2 pathway activity was increased (Figures
5D and 5E) upon CHD7 silencing (Figure S5D), which led to
increased proliferation in a BMI1-dependent fashion also in
these cells (Figure 5F).
Next, we assessed whether activation of ERK signaling was an
essential mediator of the pro-proliferative phenotype observed
upon silencing of CHD7 in G4 MB cells. Treatment of ICb1299
cells with an ERK inhibitor effectively inhibited the pathway
(Figure S5E) and led to neutralization of the increased prolifera-
tion observed upon silencing of CHD7, an effect that was also
observed in control cells (Figures 5G and 5H). Re-expression
of CHD7 in ICb1299 rescued the pro-proliferative phenotype
induced by CHD7 knockdown (Figures S3D–S3F), and it neutral-
ized the ERK pathway overactivity in these cells (Figure S5B).
Finally lentiviral-mediated overexpression of mCherry-DUSP4
(Figure S5F) in ICb1299 abolished the ERK overactivation medi-
ated by CHD7 silencing (Figures 5I–5K).
In conclusion, these data highlight a mechanism mediating a
pro-proliferative role for BMI1/CHD7 in MB G4, which impacts
ERK and is regulated by DUSP4.
CHD7 Controls Tumor Volume in a BMI1/pERK-
Dependent Fashion in Xenograft Models
To evaluate the in vivo relevance of these findings, we injected
shCHD7 ICb1299 cells, as well as shCHD7;shBMI1 and shBMI1
cells, into the cerebellum of newborn mice. Xenografted mice
were kept on tumor watch until symptoms of increased intra-
cranial pressure developed, when they were culled. Histological
analysis of the tumors did not reveal morphological differences
between MBs originating from the different conditions, including
the expression of markers such as Synaptophysin (Figure 6A)
and OTX2 (Figure S6A) and the lack of expression of GAB1 (Fig-
ure S6B) and GLI1 (Figure S6C). Stereological assessment of tu-
mor volume revealed larger MBs in mice engrafted with shCHD7
cells, an effect that was lost upon concomitant silencing of BMI1
in the engrafted cells (Figure 6B). Increased proliferation in
shCHD7 tumors was confirmed with immunohistochemical
detection of Ki67 (Figures 6C and 6D). Silencing of CHD7 did(C) BMI1 expression in G4 MB cells and in NSC197 is higher than adult cerebellu
(D and E) Silencing of CHD7 in NPCs leads to ERK1/2 pathway overactivation, a
(F) Increased proliferation is seen upon CHD7 silencing in NPCs, a finding that is
(G) Increased proliferation as assessed by EdU pulse/chase is dependent on E
inhibition of ERK in ICb1299.
(H) Quantification of the findings.
(I and J) Overexpression of exogenous mCherry-DUSP4 abolishes ERK signaling o
transduced with empty LeGO control or LeGO-mCherry-DUSP4 and quantificati
(K) Immunofluorescence of ICb1299 transduced as described in (I). Green arrows i
a cell overexpressing DUSP4 and devoid of ERK phosphorylation. Scale bar rep
See also Figure S5.
2780 Cell Reports 21, 2772–2784, December 5, 2017not affect intraparenchymal invasion, while silencing of BMI1
alone significantly hampered tumor cell invasion (Figure S6D),
in keeping with previous reports (Merve et al., 2014). Overactivity
of the ERK pathway was confirmed in the shCHD7 xenografts
(Figure 6E).
Together, these data support the conclusion that CHD7 deple-
tion enhances proliferation of G4 MB cells via a BMI1/pERK
mechanism.
DISCUSSION
The PcG gene BMI1 is upregulated in a variety of cancers, where
it correlates with clinical grade/stage and a poor prognosis.
Importantly, it is a highly druggable molecule; hence, under-
standing its mechanism of action in tumorigenesis will be essen-
tial to guide the further development and clinical testing of BMI1
pharmacological inhibitors.
Here we show that genome-wide in vivo insertional mutagen-
esis (T2Onc2) driven by the Sleeping Beauty (SB11) transposase
in glutamatergic progenitor cells engineered to overexpress
Bmi1 results in MB formation. In a Bmi1-overexpressing back-
ground, we observe frequent T2Onc2-inactivating insertions in
the chromatin remodeling factor Chd7 (Bajpai et al., 2010; Whit-
taker et al., 2017), suggesting that Bmi1 overexpression and
Chd7 loss of function cooperate to induce MB. Importantly, we
show the relevance of this molecular convergence for human
MB. In fact, high expression of BMI1 in combination with low
expression of CHD7 was found to be associated with a poor
prognosis in human MBs, particularly those of the G4 subgroup,
and loss-of-function mutations of CHD7 are significantly en-
riched for in this subgroup.
The Sleeping Beauty transposon mutagenesis is a powerful
in vivo screening tool for cancer gene discovery. In the context
of MB, this tool has been successfully used to identify candidate
genes, particularly in the context of SHH MB as expected when
using Math1 drivers; however, many of the candidate genes
identified with this tool are known to be overexpressed or
silenced in non-SHH models of the human disease (Dey et al.,
2013; Genovesi et al., 2013; Mumert et al., 2012; Wu et al.,
2012). We have studied the molecular convergence of BMI1/
CHD7 in G4MBbecause of the results of mutation analysis in hu-
man tumors indicating that genetic lesions leading to reduced
CHD7 expression are found almost exclusively in G4 MB—and
never in SHH MB—and because of the negative prognostic cor-
relation of the BMI1High;CHD7Low signature found exclusively in
G4 MB. Thus, while we initially sought to model the effects andm, as shown by western blot analysis.
s shown by western blot analysis (D) and quantification (E) (n = 2).
neutralized by incubation with a BMI1 inhibitor (n = 3).
RK1/2 overactivity, as demonstrated by its reduction upon pharmacological
veractivation mediated by CHD7 silencing. Western blot analysis (I) of ICb1299
on (J) (n = 3).
ndicate CHD7-silenced cells with ERK overactivation, while red arrow indicates
resents 25 mm. Data are represented as mean ± SEM.
Figure 6. Increased Tumor Volume in CHD7-Silenced Xenografts of G4 MB Is BMI1 Dependent
(A) Orthotopic xenografts of G4 MB cells silenced for CHD7 or CHD7;BMI1 or BMI1 show similar morphology, and they express Synaptophysin.
(B) Increased tumor volume upon injection of shCHD7 G4 MB cells, which is neutralized by concomitant silencing of BMI1.
(C) Increased proliferation, as assessed by Ki67 staining, in shCHD7 xenografts is shown together with its BMI1 dependency.
(D) Quantification of the findings.
(E) Overactivation of the ERK pathway is seen in shCHD7 xenografts. Scale bar represents 2 mm (A) and 125 mm (C and E).
Data are represented as mean ± SEM. See also Figure S6.consequences of BMI1 overexpression in an SHH model of MB,
this forward genetic screen uncovered a molecular axis whose
signaling modulates the pathogenesis of a proportion of human
G4 MBs instead. Interestingly, there is mounting evidence of a
glutamatergic cell of origin for at least a proportion of G4 MBs,
as recently suggested by a computational reconstruction of
core regulatory circuitry that identified subgroup-specific tran-
scription factors (Lin et al., 2016), hence highlighting a potential
ontogeny link between the discovery tool we used and the mo-lecular signature we have identified. Further studies in geneti-
cally engineered mouse models will confirm or dispute this
hypothesis.
We have used primary G4 MB cells to dissect the contribution
of CHD7 to tumorigenesis, both in vitro and in vivo in a xenograft
model. We show deregulated expression of neural differentiation
markers upon silencing of CHD7, an effect that is in keeping with
a pro-neurogenic role of CHD7 as previously described (Feng
et al., 2013; Jones et al., 2015). Genome-wide analysis of geneCell Reports 21, 2772–2784, December 5, 2017 2781
expression upon CHD7 silencing reveals many more upregu-
lated genes as compared to downregulated genes, in keeping
with CHD7 functioning as a repressor in our experimental setting.
This is in agreement with a reported role of CHD7 as a repressive
modulator of embryonic stem cell (ESC)-specific gene expres-
sion via targeting enhancer regions (Schnetz et al., 2010). In
keeping with CHD7 functioning as a repressor in our experi-
mental setup, no synergism between CHD7 and SOX2 was
observed, an interaction known to lead to gene activation (Enge-
len et al., 2011). SOX4 and 11 are also unlikely to mediate CHD7
function in our setting, because CHD7 promotes an open chro-
matin configuration at their promoters (Feng et al., 2013).
We show increased proliferation of G4 MB cells upon CHD7
silencing in vitro as well as increased tumor volume upon ortho-
topic xenografting of these cells into NOD/SCID mice, an effect
that is dependent on BMI1 expression. Bioinformatic analysis of
the deregulated genes identified in a comparative gene expres-
sion analysis with human MB datasets revealed a BMI1-depen-
dent convergence onmodulation of ERK signaling via repression
of DUSP4 in CHD7-depleted cells. Meta-analysis of publicly
available ChIP-seq and RNA-seq datasets (Gargiulo et al.,
2013) confirmed that DUSP family members are direct target
genes of Bmi1.We provide evidence of altered chromatin acces-
sibility at the promoter of DUSP4 upon CHD7 silencing. This is in
keeping with the recently reported ability of CHD7 to alter chro-
matin accessibility in primary cerebellar granule neuron progen-
itors (Feng et al., 2017; Whittaker et al., 2017), and it provides
support to the notion that PcG-mediated gene repression is
counteracted by a compacted chromatin configuration induced
byCHD7 inG4MBcells. Our findings are in good agreement with
a previously reported role for DUSP4 in promoting neuronal dif-
ferentiation and repressing proliferation via repression of the
ERK pathway (Kim et al., 2015). Furthermore, activation of ERK
signaling has been shown to control a proneural genetic program
during cortical development and to activate an Ascl1-controlled
neuronal differentiation program (Li et al., 2014). Overactivity of
the pathway was found to exert a pro-proliferative role in SHH
MBs (Brechbiel et al., 2014; Sengupta et al., 2012) and in other
brain tumors, pilocytic astrocytomas, and glioneuronal tumors
(Li et al., 2014). We show that activation of ERK signaling via
the repression of DUSP4 by BMI1 is not found in a G3 MB line,
lending additional support to the conclusion that this molecular
convergence is functionally relevant only in a subset of G4
MBs. Pharmacological inhibition of ERK signaling confirmed
the functional relevance of this regulatory loop in the G4MB lines
analyzed. Finally, silencing CHD7 in human neural progenitor
cells expressing high levels of BMI1 induced overactivation of
the ERK pathway and increased proliferation of these cells
in vitro. These data raise the possibility that a BMI1High;CHD7Low
signature is oncogenic in human progenitor cells; genetically en-
gineered models recapitulating this signature in a spatiotempo-
rally controlled fashion will be essential to test this hypothesis.
The reversible nature of epigenetic modifications makes them
attractive therapeutic targets, and pharmacological agents that
can potentially reverse altered chromatin states are undergoing
trials. Our findings extend the current knowledge of the role of
two essential chromatin modifiers, BMI1 and CHD7, in MB path-
ogenesis, and they raise the possibility that pharmacological tar-2782 Cell Reports 21, 2772–2784, December 5, 2017geting of BMI1may be particularly indicated in a subgroup of MB
with low expression level of CHD7. Alternatively, the use of ERK
inhibitors could also be further explored for MB treatment, and
we provide here essential preclinical evidence that BMI1 and
CHD7 could be useful biomarkers to define the patient subgroup
that could benefit from this approach.
EXPERIMENTAL PROCEDURES
Detailed methods are available in the Supplemental Experimental Procedures.
Sleeping Beauty Mutagenesis
Male and female Math1-Bmi1, Math1-Bmi1;SB11;T2Onc2, or T2Onc2 mice
(12 to 20 weeks of age; at the time they developed signs of MB) were used.
We did not perform a formal sample size estimate for the study but based
our experimental plan on our previous experience with Sleeping Beauty muta-
genesis screening. When mice showed clinical signs of increased intracranial
pressure, they were culled, the brains were removed, and they were either
fixed in formalin for histological assessment or used for genomic DNA extrac-
tion. All the procedures involving animals have been approved by the institu-
tional Animal Care Committee and in no case were tumor-bearing animals
allowed to reach a tumor burden compromising normal behavior, food and
water intake, or exceeding the approved volume of 1,700 mm3.
Culture Conditions for Patient-Derived MB Lines
Patient-derivedMB lines were obtained from Dr Xiao-Nan Li, Baylor College of
Medicine, Texas Children Cancer Centre, USA (Shu et al., 2008; Zhao et al.,
2012). ICb1299 was cultured in DMEM (high glucose, GlutaMAX, Thermo
Fisher Scientific) supplemented with 10% fetal bovine serum and 1% peni-
cillin-streptomycin. ICb1595, ICb984, and ICb1338 were cultured in NeuroCult
NS-A Basal Medium (human) (STEMCELL Technologies) supplemented
with NeuroCult Proliferation Supplement (human) (STEMCELL Technologies),
1% penicillin-streptomycin, 2 mg/mL heparin (STEMCELL Technologies),
20 ng/mL epidermal growth factor (EGF) (recombinant mouse, PeproTech),
and 10 ng/mL basic fibroblast growth factor (bFGF) (human recombinant,
PeproTech). ICb1595, ICb984, and ICb1338 were cultured on plates coated
with Poly-L-ornithine and Laminin (Sigma). CHLA-01-Med was purchased
from ATCC (CRL3021) and grown in DMEM-F12 (Gibco) supplemented with
B27 (Gibco), 20 ng/mL EGF, and 10 ng/mL bFGF. Cells were maintained at
37C and were sub-cultured every 3 days once they reached confluence.
Proliferation Assay
Patient-derived cells infected with lentiviral constructs coding for shBMI1 and/
or shCHD7 were analyzed with cell growth curve and EdU staining to assess
their proliferation potential compared to scramble control.
In Vivo Orthotopic Xenografts
All procedures had Home Office approval (Animals Scientific Procedures
Act 1986, PPL 70/7275) and were carried out as previously reported (Merve
et al., 2014). Mice were killed when developing neurological signs and brains
were removed andplaced in 10%formalin for 24 hr and then transferred toPBS.
Inhibition of MEK/ERK Activity
Patient-derived cells were treated with the MEK inhibitors PD98059 (Cell
Signaling Technology) or U0126 (Cell Guidance Systems) at different concen-
trations. After 1 hr of treatment, cells were harvested and lysed for protein
analysis. Alternatively, to assess proliferation potential, cells were treated
twice with U0126 (50 mM) before pulsing with EdU or collecting them for west-
ern blot analysis.
Western Blot Analysis
Total protein extracts were prepared with radioimmunoprecipitation assay
(RIPA) buffer supplemented with protease inhibitors. Nuclear protein extracts
were obtained as previously described (Badodi et al., 2015). Equal amounts of
protein extracts were separated by SDS-PAGE and analyzed by western blot
analysis.
Statistical Analysis
Differences between groups were determined by one-way ANOVA, followed
by Dunnett’s post hoc test (ATAC experiments) or Tukey’s multiple compari-
son test (all other experiments) to determinewhich groups differed significantly
from control. Any p values < 0.05 were considered significant (*p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and two data files and can be found with this article online at
https://doi.org/10.1016/j.celrep.2017.11.021.
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